The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with gemcitabine and cisplatin chemotherapy as a neoadjuvant treatment before bladder ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and chemotherapy both before and after surgery were ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk ...

Over the last week, AstraZeneca's share price increased by 1%, aligning closely with the broader market's growth of 2%. While ...

Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes tumors more aggressive and difficult to treat. Colon cancer is the third ...